Cantargia AB (CANTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cantargia AB (CANTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8228
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It utilizes cell surface receptor as a target to develop a novel antibody based therapy for the treatment of chronic myeloid leukemia and other forms of leukemia. Cantargia provides therapies for the treatment of hematological malignancies that uses the expression of cell surface receptor on hematopoietic stem cells. The company also develops antibody therapeutics to eradicate the leukemia disease causing stem cells. Cantargia is headquartered in Lund, Sweden.

Cantargia AB (CANTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cantargia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cantargia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cantargia AB, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Cantargia Raises USD3 Million in Venture Financing 11
Cantargia Raises USD0.46 Million in Venture Financing 12
Cantargia Raises US$1 Million In Venture Financing 13
Partnerships 14
Cantargia and Panorama Research Enter into Co-Development Agreement 14
Licensing Agreements 15
Cantargia Enters into Licensing Agreement with BioWa 15
Equity Offering 16
Cantargia Raises USD7.7 Million in Rights Offering of Shares 16
Cantargia Raises USD2.8 Million in Private Placement of Shares upon Exercise of Warrants 17
Cantargia Plans to Raise upto USD12.2 Million 18
Cantargia Raises Funds through Private Placement of Shares upon Exercise of Warrants 19
Cantargia Raises USD4 Million in Private Placement of Shares upon Exercise of Warrants 20
Cantargia to Raise USD0.5 Million in Private Placement of Shares up on Exercise of Warrants 21
Cantargia Raises USD5.13 Million in IPO 22
Cantargia Raises USD0.07 Million in Private Placement of Shares up on Exercise of Warrants 23
Cantargia AB – Key Competitors 24
Cantargia AB – Key Employees 25
Cantargia AB – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 21, 2018: Cantargia publishes 2018 half year report 27
May 15, 2018: Cantargia publishes interim report for first quarter 2018 28
Feb 28, 2018: Cantargia publishes year end report for 2017 29
Nov 08, 2017: Cantargia publishes interim report for third quarter of 2017 30
Aug 23, 2017: Cantargia publishes half year report 31
Mar 15, 2017: Cantargia publishes year-end report for 2016 32
Corporate Communications 33
Sep 25, 2018: Nasdaq Stockholm welcomes Cantargia to the main market 33
Jul 13, 2018: Cantargia approved for listing on Nasdaq Stockholm First North Premier as part of the process towards Nasdaq Stockholm’s main market 34
May 19, 2017: Cantargia strengthens organisation with CFO 35
Product News 36
10/13/2017: Cantargia announces first patient treated and completed a three weeks safety evaluation period with immuno-oncology antibody CAN04 36
07/21/2017: Cantargia Gains Approval to Initiate the CANFOUR Clinical Trial of Immuno-oncology Product Candidate CAN04 37
06/19/2018: Cantargia’s immuno-oncology antibody CAN04 has obtained the INN nidanilimab by WHO 38
05/16/2018: Cantargias immuno-oncology project CAN04 shows promise in additional cancer forms 39
03/15/2018: Cantargia Presents New Data at AACR on Inhibition of Metastasis by Antibodies Against IL1RAP 40
01/05/2017: Cantargia’s research and development to be presented at Biotech Showcase in San Francisco on 9 January 2017 41
Product Approvals 42
May 12, 2017: Cantargia’s Application to Investigate the Antibody Product Candidate CAN04 in the CANFOUR Phase I/IIa Clinical Trial has been Submitted 42
Clinical Trials 43
Apr 16, 2018: Cantargia presents anti-metastatic effect of IL1RAP blocking antibody at AACR 43
Mar 06, 2018: Cantargia: antibody against ILRAP reduce metastases in experimental cancer model 44
Jun 26, 2017: Cantargia: Preclinical studies of IL1RAP and CAN04 in solid tumours presented at EACR-AACR-SIC in Florence 45
May 08, 2017: Cantargia’s product candidate CAN04 shows good safety properties in studies performed under GLP 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Cantargia AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cantargia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cantargia AB, Deals By Therapy Area, 2012 to YTD 2018 9
Cantargia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cantargia Raises USD3 Million in Venture Financing 11
Cantargia Raises USD0.46 Million in Venture Financing 12
Cantargia Raises US$1 Million In Venture Financing 13
Cantargia and Panorama Research Enter into Co-Development Agreement 14
Cantargia Enters into Licensing Agreement with BioWa 15
Cantargia Raises USD7.7 Million in Rights Offering of Shares 16
Cantargia Raises USD2.8 Million in Private Placement of Shares upon Exercise of Warrants 17
Cantargia Plans to Raise upto USD12.2 Million 18
Cantargia Raises Funds through Private Placement of Shares upon Exercise of Warrants 19
Cantargia Raises USD4 Million in Private Placement of Shares upon Exercise of Warrants 20
Cantargia to Raise USD0.5 Million in Private Placement of Shares up on Exercise of Warrants 21
Cantargia Raises USD5.13 Million in IPO 22
Cantargia Raises USD0.07 Million in Private Placement of Shares up on Exercise of Warrants 23
Cantargia AB, Key Competitors 24
Cantargia AB, Key Employees 25

List of Figures
Cantargia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cantargia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cantargia AB (CANTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mikros Systems Corporation:企業の戦略・SWOT・財務分析
    Mikros Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Mikros Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Temple University-医療機器分野:企業M&A・提携分析
    Summary Temple University (Temple) is an educational and research university that offers undergraduate and graduate courses. The university offers undergraduate courses in various fields which include arts, media and communication, medicine, engineering, pharmacy and others. Temple offers its degree …
  • Sunshine Oilsands Ltd (2012):企業の財務・戦略的SWOT分析
    Summary Sunshine Oilsands Ltd (Sunshine Oilsands) is an oil and gas company that develops holdings of oil sands and PN&G leases. The company owns and controls oil sands leases. Its properties include Thickwood, West Ells, Muskwa, Harper, Legend Lake and Portage, among others. Sunshine Oilsands also …
  • Distributed Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Distributed Bio Inc (Distributed Bio) is a provider of bioinformatics services. The company offers support of genomic technologies including NextGen sequencing, antibody informatics and computational bioengineering. It provides modern laboratory information management system to manage sequen …
  • Ondine Biomedical Inc:企業の製品パイプライン分析2018
    Summary Ondine Biomedical Inc (Ondine), formerly Ondine Biopharma Corp, a subsidiary of 0902337 B.C. Ltd, is a non-antibiotic anti-infective therapies developer for bacterial, viral, and fungal infections. The company’s products include periowave systems, MRSAid systems, sinuwave systems, exelume sy …
  • Biomay AG-製薬・医療分野:企業M&A・提携分析
    Summary Biomay AG (Biomay) discovers and develops disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. Its pipeline product portfolio comprises investigation candidates targeted against IgE mediated diseases, grass pollen allergy, ho …
  • Argon Medical Devices Inc-医療機器分野:企業M&A・提携分析
    Summary Argon Medical Devices Inc (Argon) is a medical device company that manufactures and supplies products for the dialysis and others. The company provides arterial catheters, temporary pacing electrode trays, pulmonary artery and thermodilution catheters, and single lumen central venous cathete …
  • Coherent Inc (COHR):企業の財務・戦略的SWOT分析
    Coherent Inc (COHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Danville Materials Inc:医療機器:M&Aディール及び事業提携情報
    Summary Danville Materials Inc (Danville), a subsidiary of Inverness Graham Investments is a medical device company that manufactures dental equipment. The company provides posts, air abrasion, tin plating, adhesives, sand blasting, composites, air polishing, dust cabinets, microetcher, and IPR. It …
  • Concordia International Corp (CXR)-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products compr …
  • Amerisur Resources Plc (AMER):石油・ガス:M&Aディール及び事業提携情報
    Summary Amerisur Resources Plc (Amerisur) is an independent full cycle oil and gas company. It focuses on the exploration, development and production of oil and natural gas in onshore South America, primarily in Colombia and Paraguay. Amerisur has working interests in the Platanillo - OBA cluster, P …
  • Groupe Le Duff S.A.(Foodservice):戦略・SWOT・企業財務分析
    Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Lario Oil & Gas Company:石油・ガス:M&Aディール及び事業提携情報
    Summary Lario Oil & Gas Company (Lario Oil & Gas) is an oil and gas exploration and production company that explores and produces oil and gas properties. The company offers services such as discovering reserves organically from geologic thesis, drill-bit, field delineation, and land acquisition and …
  • The E. W. Scripps Company:企業の戦略・SWOT・財務情報
    The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report Summary The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CardioDx Inc:医療機器:M&Aディール及び事業提携情報
    Summary CardioDx Inc (CardioDx) is a cardiovascular genomic diagnostics company. It undertakes the development of clinically validated tests in the areas of coronary artery disease, cardiac arrhythmias and heart failure. The company’s flagship product, Corus CAD gene expression test is used for asse …
  • Envision Solar International Inc (EVSI):電力:M&Aディール及び事業提携情報
    Summary Envision Solar International Inc (Envision Solar) is a provider of energy security systems. The company's products include renewably energized electric vehicle charging systems, media and branding systems, energy security systems, patented solar tracking systems, energy storage systems, elec …
  • Entergy Corporation:企業の戦略・SWOT・財務情報
    Entergy Corporation - Strategy, SWOT and Corporate Finance Report Summary Entergy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • JG Summit Holdings Inc:企業の戦略・SWOT・財務情報
    JG Summit Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary JG Summit Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Gene Techno Science Co Ltd (4584)-製薬・医療分野:企業M&A・提携分析
    Summary Gene Techno Science Co Ltd (GTS) is a developer and marketer of drug and antibodies for cancer, intractable diseases and rare diseases. The company develops biological and biosimilar products. Its biological pipeline products include GND-001 for immunological disease and oncology; GND-004, f …
  • Mapletree Greater China Commercial Trust Management Ltd:企業の戦略・SWOT・財務情報
    Mapletree Greater China Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Mapletree Greater China Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆